The pathway to secondary prevention of Alzheimer's disease.

Download
Citations
Altmetric
Author
McDade, E; Bednar, MM; Brashear, HR; Miller, DS; Maruff, P; Randolph, C; Ismail, Z; Carrillo, MC; Weber, CJ; Bain, LJ; ...Date
2020Source Title
Alzheimer's and Dementia: Translational Research and Clinical InterventionsPublisher
WileyUniversity of Melbourne Author/s
Maruff, PaulAffiliation
Anatomy and NeuroscienceMetadata
Show full item recordDocument Type
Journal ArticleCitations
McDade, E., Bednar, M. M., Brashear, H. R., Miller, D. S., Maruff, P., Randolph, C., Ismail, Z., Carrillo, M. C., Weber, C. J., Bain, L. J. & Hake, A. M. (2020). The pathway to secondary prevention of Alzheimer's disease.. Alzheimers Dement (N Y), 6 (1), pp.e12069-. https://doi.org/10.1002/trc2.12069.Access Status
Open AccessOpen Access at PMC
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7453146Abstract
Alzheimer's disease (AD) is a continuum consisting of a preclinical stage that occurs decades before symptoms appear. As researchers make advances in investigating the continuum, the importance of developing drugs for secondary prevention is garnering increased discussion. For efficacious drug development for secondary prevention it is important to define what are the earliest biological stages of AD. The Alzheimer's Association Research Roundtable convened November 27 to 28, 2018 to focus on pre-clinical AD. This review will address the biological approach to defining pre-clinical AD, detection, identification of at-risk individuals, and lessons learned from trials such as A4 and TOMMORROW.
Export Reference in RIS Format
Endnote
- Click on "Export Reference in RIS Format" and choose "open with... Endnote".
Refworks
- Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References